AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.2700
-0.0090 (-3.23%)
At close: Oct 5, 2026, 4:00 PM EDT
0.2668
-0.0032 (-1.19%)
Pre-market: Oct 6, 2026, 8:44 AM EDT
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
13.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vistagen Therapeutics | 2.50M |
| BioLineRx | 1.39M |
| Daré Bioscience | 1.37M |
| Vyome Holdings | 129.73K |
| Lisata Therapeutics | 100.00K |
AEON News
- 5 days ago - Aeon Biopharma price target raised to $2 from $1 at Lake Street - TheFly
- 6 days ago - Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450 - TheFly
- 6 days ago - AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 - GlobeNewsWire
- 27 days ago - Aeon Biopharma announces results from ABP-450 pilot forced degradation study - TheFly
- 27 days ago - AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - GlobeNewsWire
- 27 days ago - Aeon Biopharma initiated with a Buy at Laidlaw - TheFly
- 5 weeks ago - AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference - GlobeNewsWire
- 6 weeks ago - Aeon Biopharma designates Paul Lee as acting chief regulatory officer - TheFly